John Moroney, MD

John Moroney, MD

Gynecologic Oncology

Accepts New Patients

Download Contact Information

Request Appointment

Please call the office to schedule an appointment with this provider.

Call the Office

Back to Top

Locations

A

Hinsdale

UChicago Medicine AdventHealth Gynecologic Oncology Hinsdale
1 Salt Creek Lane
Suite 100
 Hinsdale, IL  60521
630-286-5500
B

Chicago

University of Chicago Gynecologic Oncology
5841 S Maryland
 Chicago, IL  60637
773-702-6721
Back to Top

UChicago Faculty Physicians hold faculty positions with the University of Chicago and provide care for patients on the academic health system's main campus in Hyde Park and in care centers throughout the Chicago region. UChicago Faculty Physicians who provide services at UChicago Medicine AdventHealth Bolingbrook, Hinsdale, La Grange and GlenOaks hospitals are independent providers with privileges at those hospitals. Except as otherwise denoted, independent providers are not employees or agents of UChicago Medicine AdventHealth Bolingbrook, Hinsdale, La Grange and GlenOaks hospitals.

Expertise

Biography

John Moroney, MD is board-certified in Gynecologic Oncology. His specialties include:

  • Gynecologic Oncology
  • Clinical Trials
  • Cervical Cancers
  • Uterine Cancer
  • Ovarian Cancer
  • Abnormal Placentation
  • Fertility- Sparing Surgery
    • Care Philosophy

    Dr. Moroney believes that access to state-of-the-art surgical techniques and medical therapies are vital in achieving the best possible outcomes. He specializes in the treatment and diagnosis of gynecologic cancers, with an emphasis on providing skilled and personalized care.

    Dr. Moroney serves as the principal investigator for numerous industry-sponsored clinical trials. He is the principal investigator for NRG Oncology, a National Cancer Institute – supported cooperative group for clinical trials at the University of Chicago.

    Areas Served
    Hinsdale, IL | Chicago, IL
    Languages Spoken
    English
    Education
    • Loyola University of Chicago Stritch School of Medicine
    Residencies
    • Obstetrics and Gynecology at Walter Reed National Military Medical Center
    Fellowships
    • Gynecologic Oncology at M.D Anderson Cancer Center
    Medical Organization Memberships and Committees
    • American Society of Clinical Oncology
    • American College of Obstetricians and Gynecologist
    • Society of Gynecologic Oncology

      More items loaded

    Board Certification
    • Gynecologic Oncology: The American Board of Obstetrics and Gynecology
    • Obstetrics & Gynecology: The American Board of Obstetrics and Gynecology
    Publications
    • Rimel BJ, Enserro D, Bender DP, Jackson CG, Tan A, Alluri N, Borowsky M, Moroney J, Hendrickson AW, Backes F, Swisher E, Powell M, MacKay H. NRG-GY012 Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 Apr 15; 130(8)1234-1245. PMID 38127487; PMCID PMC11168450.
    • Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T, Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Gro. Mirvetuximab Soravtansine in FRa-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 07; 389(23)2162-2174. PMID 38055253.
    • O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium NRG oncology/gynecologic oncology group study 0283. Gynecol Oncol. 2023 09; 17616-24. PMID 37418832; PMCID PMC10529107.

      More items loaded

    • Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UA. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9)1317-1322. PMID 35900726; PMCID PMC9335244.
    • Chen S, Xie P, Cowan M, Huang H, Cardenas H, Keathley R, Tanner EJ, Fleming GF, Moroney JW, Pant A, Akasha AM, Davuluri RV, Kocherginsky M, Zhang B, Matei D. Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. J Clin Invest. 2022 07 15; 132(14). PMID 35671108; PMCID PMC9282926.
    • Slomovitz BM, Filiaci VL, Walker JL, Taub MC, Finkelstein KA, Moroney JW, Fleury AC, Muller CY, Holman LL, Copeland LJ, Miller DS, Coleman RL. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3) 481-491-PMID 35063278.
    • Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJ. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20)5510-5518. PMID 34168049.
    • Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez C, Janisch LA, Hseu RD, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24)6437-6444. PMID 33028595; PMCID PMC8561652.
    • Moroney JW, Powderly J, Lieu CH, Bendell JC, Eckhardt SG, Chang CW, Molinero L, Spahn J, Williams P, Lin YG, Hodi FS. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer A Phase Ib Study. Clin Cancer Res. 2020 11 01; 26(21)5631-5637. PMID 32723836.
    • Kurnit KC, Reid P, Moroney JW, Fleming GF. Immune checkpoint inhibitors in women with gynecologic cancers Practical considerations. Gynecol Oncol. 2020 09; 158(3) 531-537-PMID 32641238.
    • Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P, Färkkilä A. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Aug 01; 5(8)1141-1149. PMID 31194228; PMCID PMC6567832.
    • Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019 07; 69(4) 258-279-PMID 31074865.
    • Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16)1611-1618. PMID 29437535.
    • Son CH, Fleming GF, Moroney JW. Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. Cancer Manag Res. 2017; 9553-563. PMID 29184441; PMCID PMC5672877.
    • Rojas C, Moroney JW. Robotic surgical staging for cervical cancer diagnosed during pregnancy Immediate versus delayed definitive treatment. Gynecol Oncol Case Rep. 2013; 540-2. PMID 24371693; PMCID PMC3862293.
    • Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20)5796-805. PMID 22927482.
    • Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21)6840-6. PMID 21890452; PMCID PMC3207033.
    • Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011 Jul 01; 29(19)e572-5. PMID 21482991.
    • Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011 Mar; 10(3)558-65. PMID 21216929; PMCID PMC3072168.
    • Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3)467-72. PMID 20347123; PMCID PMC2882061.
    • Cheng X, Moroney JW, Levenback CF, Fu S, Jaishuen A, Kavanagh JJ. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother. 2009 Nov; 21(5)566-72. PMID 19933049.
    • Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009 Jun; 5(5) 591-600-PMID 19519199; PMCID PMC2744352.
    • Frumovitz M, Soliman PT, Greer M, Schmeler KM, Moroney J, Bodurka DC, Ramirez PT. Laparoscopy training in gynecologic oncology fellowship programs. Gynecol Oncol. 2008 Nov; 111(2)197-201. PMID 18804849.
    • Moroney JW, Zahn CM. Common gynecologic problems in geriatric-aged women. Clin Obstet Gynecol. 2007 Sep; 50(3) 687-708-PMID 17762418.
    • Moroney JW, Zahn CM, Heaton RB, Crothers B, Kendall BS, Elkas JC. Normal endometrial cells in liquid-based cervical cytology specimens in women aged 40 or older. Gynecol Oncol. 2007 Jun; 105(3)672-6. PMID 17363044
    Ages Accepted
    • Adults
    Back to Top

    Frequently Asked Questions

    What locations does John Moroney, MD practice at?
    John Moroney, MD practices at Hinsdale at 1 Salt Creek Lane, Suite 100, Hinsdale, IL, 60521, Chicago at 5841 S Maryland, Chicago, IL and 60637. Learn more about John Moroney, MD at AdventHealth.
    What is John Moroney, MD's specialty?
    John Moroney, MD specializes in Gynecologic Oncology. Learn more about John Moroney, MD at AdventHealth.
    What conditions does John Moroney, MD treat?
    John Moroney, MD treats the following conditions: Anemia, Cancer and Reproductive System. Learn more about John Moroney, MD at AdventHealth.
    What health services does John Moroney, MD provide?
    John Moroney, MD provides Cancer Care services. Learn more about John Moroney, MD at AdventHealth.